Press Releases
Cairn Therapeutics Completes $4M Bridge Investment Round to Fund Startup of Phase I Clinical Trial
WILMINGTON, DE Cairn Therapeutics, Inc., (“Cairn” or the “Company”), a pharmaceutical company developing highly targeted medications for the treatment of cancer, today announced that it has completed its $4M Bridge investment round. The company intends to use the...
Cairn Therapeutics to Present at MedInvest Biotech & Pharma Investor Conference
WILMINGTON, DE Cairn Therapeutics, Inc., (“Cairn” or the “Company”), a pharmaceutical company developing highly targeted medications for the treatment of cancer, today announced that it will present an update on the company’s flagship product, CT-262, at the MedInvest...
Cairn Therapeutics Announces New Management Team and Board of Directors
Company Intends to Initiate First-in-Human Clinical Trials in Cancer Next Year WILMINGTON, DE – Cairn Therapeutics, Inc., a pharmaceutical company developing new, highly targeted medications for the treatment of oncology, today announced the formation of their new...